首页|黄芪甲苷对炎性巨噬细胞RAW264.7的免疫调控及其机制探讨

黄芪甲苷对炎性巨噬细胞RAW264.7的免疫调控及其机制探讨

扫码查看
目的 基于网络药理学和体外实验,在巨噬细胞RAW264.7上,以其免疫调变规律探究黄芪甲苷(AS-Ⅳ)防治肺炎的可能机制.方法 以Pharm Mapper、SwissTargetPrediction和STITCH数据库预测AS-Ⅳ的作用靶点,通过Genecards、DisGeNET数据库检索肺炎靶点,并获取与AS-Ⅳ作用靶点的交集;再借助STRING平台和Cytoscape软件构建交集靶点的蛋白相互作用网络,并依据degree值筛选核心靶点;利用DAVID数据库进行GO功能注释和KEGG通路富集分析,并进一步运用KEGG数据库预测AS-Ⅳ干预肺炎的可能通路.最后,据此进行体外实验:将对数生长期的巨噬细胞RAW264.7随机分成3组:对照组(C)、模型组(M)及AS-Ⅳ实验组(AS-Ⅳ).除C组外,其他2组均以LPS刺激,AS-Ⅳ组再加以AS-Ⅳ干预.CCK8法明确AS-Ⅳ对其增殖的影响;ELISA法确定各组NF-κB、IL-1β、MCP-1及Arg-1的分泌水平;以qPCR确证各组TLR4及其下游通路分子HMGB1和TLR4等的基因表达.结果 网络药理学分析显示,AS-Ⅳ有158个预测作用靶点,与肺炎交集靶点有112个.KEGG通路富集分析得到126条作用通路,结合文献确定HMGB1、TLR4、TRIF、Myd88及NF-κB为待验证通路靶点.进一步体外实验证实,AS-Ⅳ组NF-κB、IL-1β及MCP-1较M组显著降低,Arg-1则明显升高,但HMGB1、TLR4、TRIF及Myd88基因表达较M组显著减少,差异均有统计学意义.结论 AS-Ⅳ可通过HMGB1/TLR4相关信号通路调控RAW264.7的炎性免疫应答,这为临床肺炎的治疗提供了实验基础及数据支持.
Immunoregulatory effects of astragaloside Ⅳ on inflammatory macrophage RAW264.7
Based on network pharmacology and in vitro experiments,this study was performed to explore the possible mechanism of astragaloside Ⅳ(AS-Ⅳ)in the prevention and treatment of pneumonia by regulating immune function in RAW264.7 macrophages.Pharm Mapper,SwissTargetPrediction and STITCH databases were used to predict the target sites of AS-Ⅳ,while Genecard and DisGeNET databases were used to retrieve the pneumonia targets,and the intersection with AS-Ⅳ targets was obtained.Then STRING platform and Cytoscape software were used to construct the protein interaction network of the intersection targets,and the core targets were selected according to the degree value.The DAVID database was used for GO functional annotation and KEGG pathway enrichment analysis,and the KEGG database was further used to predict the possible pathways of AS-Ⅳ intervention in pneumonia.For in vitro experiment,macrophage RAW264.7 of logarithmic phase were randomly divided into 3 groups:control group(C),model group(M)and the AS-Ⅳ group(AS-Ⅳ).Except for group C,the other two groups were stimulated with LPS,and the AS-Ⅳ group was further intervened by AS-Ⅳ.CCK8 method was used to determine the effect of AS-Ⅳ on the proliferation of RAW264.7 cells;ELISA was used to determine the secretion levels of NF-κB,IL-1β,MCP-1 and Arg-1;qPCR was used to detect the gene expression of TLR4 and its downstream pathway molecules HMGB1 and TLR4 in each group.Network pharmacological analysis predicted that AS-Ⅳ had 158 targets and 112 intersection targets with pneumonia,while the enrichment analysis of KEGG pathway obtained 126 pathways.In consider with literature,HMGB1,TLR4,TRIF,Myd88 and NF-κB were identified as the target of pathway to be verified.Further in vitro experiments confirmed that NF-κB,IL-1β and MCP-1 in AS-Ⅳ group were significantly decreased as compared with M group,while Arg-1 was significantly increased,the expression of HMGB1,TLR4,TRIF and Myd88 genes were significantly decreased as compared with M group.Taken together,AS-Ⅳ can regulate the inflammatory immune responses of RAW264.7 through HMGB1/TLR4 related signaling pathways,which provides experimental basis and data support for clinical pneumonia treatment.

Astragaloside ⅣInflammatory macrophageImmune regulationHMGB1TLR4

刘柯、贾淑红、丁军颖

展开 >

100010,首都医科大学附属北京中医医院北京市中医药研究所中医感染性疾病基础研究北京市重点实验室

100010,首都医科大学附属北京中医医院北京市中医药研究所老年病科

黄芪甲苷 炎性巨噬细胞 免疫调控 HMGB1 TLR4

2024

免疫学杂志
第三军医大学,中国免疫学会

免疫学杂志

CSTPCD
影响因子:0.704
ISSN:1000-8861
年,卷(期):2024.40(7)